A cystic fibrosis patient homozygous for the nonsense mutation R553X was identified by mutation screening and the genotype confirmed by DNA sequencing. This patient, the only one described to date who is homozygous for this stop codon in exon 11 of the CFTR gene, is moderately severely affected. Clinical and molecular findings are presented.
compound heterozygosity for stop mutations have been published. Cuppens et a16 reported on a mildly affected patient who was homozygous for G542X and Cutting et a17 described two mildly affected patients with the genotypes W1316X/H553X and S1255X/G542X, respectively. We report here on a moderately severely affected patient who is homozygous for the nonsense mutation R553X.
Methods
One hundred and thirty-nine German cystic fibrosis patients with at least one non-AF508 allele were screened for mutations in exon 11 of the CFTR gene with restriction enzymes HincII and MboI.3 Seventeen of the total of 177 non-AF508 chromosomes exhibited the loss of a HincII site without the creation of a new MboI site. One patient was found to be homozygous for this type of deviation.
PCR amplified DNA of this patient encompassing the entire exon 11 was then directly sequenced on an automated fluorescence sequencer (Applied Biosystems, Foster City, model 373A) using protocols and labelled primers supplied by the vendor.
Case report
The proband was the first child born to healthy parents of German origin who are second degree relatives. His birth weight was 2950 g and length 52 cm. Failure to thrive was noted at the age of 16 months. He started to produce copious fatty stools and developed rectal prolapse.
Sweat tests were initially in the normal range, but soon became borderline and were clearly positive with 160 mEq/l sodium chloride at the age of 2 years 4 months. The patient suffered from a recurrent cough and developed pronounced pulmonary manifestations of CF with chronic obstructive bronchitis and peribronchitis. Staphylococcus aureus and Pseudomonas aeruginosa were found in his sputum from this age onwards. Lung function was only moderately affected when tested repeatedly between the ages of 11 and 13j years. Oral glucose tolerance was impaired at 11 years 9 months suggesting latent diabetes mellitus; stool chymotrypsin was then 111 U/g. Bal, Stuhrmann, Schloesser, Schmidtke, Reiss Pancreatic enzyme substitution therapy was started at 2 years 4 months of age. Whereas height was between the 25th and the 50th centile throughout the time period assessed (2 years 4 months to 131 years), his weight ranged only between well below the 3rd and the 10th centile. In view of this clinical picture, we tentatively classified this phenotype as moderately severe.
The sequence analysis of exon 11 of the patient is shown in the figure. Apart 
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